ReviewTrends in cell biology2026
Tetraploids or polyploid giants: who is truly dangerous?
Review in Trends in cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tetraploidy, resulting from a single whole-genome duplication (WGD) event, contributes to tumorigenesis by promoting genomic instability and functional diversity. In general, WGD beyond tetraploidy limits proliferative and tumorigenic potential, but an increasing number of studies suggest that polyploid giant cancer cells (PGCCs)-large, highly polyploid (≥8N) cells formed in response to chemotherapy-produce daughter cells with reduced DNA content that drive cancer progression. In this opinion article, we examine the literature on tetraploid cells and PGCCs from a cell biology perspective. It is our opinion that the role of tetraploidy in cancer is supported by findings from cell lines, animal models, and tumor sequencing data, while definitive evidence that viable progeny from PGCCs can promote cancer progression in human tumors is lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.